Skip to main content

DE&I Resource Center

Diversity in Clinical Trials

Diversity in Clinical Trials

Clara Health: Nothing for Us Without Us: Building Inclusive Clinical Trials for the LGBTQ Community
In addition to experiencing stigma, discrimination, and a denial of civil and human rights, many members of the LGBTQ community are omitted from clinical trials. And when it comes to testing new drugs, therapies, and devices, there is a huge lack of needed diversity in clinical trials.

ACRP: Calls for Renewed Efforts to Diversify Clinical Trials Workforce
Calling for a concerted effort to promote diversity in the clinical trials workforce, Association of Clinical Research Professionals (ACRP) said that now is the time to raise awareness of clinical research as a vibrant career option among minority populations too often overlooked by the drug and device research and development industry.

Novartis: Building Clinical Trial Diversity for Long-Term Equity
We need to study populations where we ultimately use our medicines to understand the efficacy and safety of these medicines. In many cases, we learn, often after the fact, that we can see different profiles of medicines, depending on race, ethnicity, genetic factors, etc. Also, we know that when you do clinical trials in healthcare systems, you build a positive ecosystem to adopt new technologies.

Pfizer: Clinical Trial Diversity Report
This analysis includes Pfizer interventional clinical trials that initiated enrollment between 2011 through 2020. The data set comprises 213 trials with 103,103 US participants. The analysis also examined the percentage of trials that achieved racial and ethnic distribution levels at or above census levels. The results presented here provide a baseline upon which we can quantify the impact of our ongoing efforts to improve racial and ethnic diversity in clinical trials.

U.S. FDA: Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry
This guidance recommends approaches that sponsors of clinical trials intended to support a new drug application or a biologics license application can take to increase enrollment of underrepresented populations in their clinical trials.

This Resource Center has been created to complement your DE&I initiatives and/or strategies. The links and information included in this Resource Center are suggestions to help you on your individual/company journey and is in no way an exhaustive list of what is available. The vendors listed have not been endorsed by Biocom California.